The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics - New Venture Co.

6 May 2005 07:00

Angle PLC06 May 2005 For Immediate Release 6 May 2005 ANGLE plc GEOMERICS: NEW VENTURE COMPANY ANGLE plc ("ANGLE"), the venture management and consulting company specialisingin the commercialisation of technology, is pleased to announce the launch of itslatest venture company, Geomerics Ltd ('Geomerics'). Geomerics has secured intellectual property in the field of geometric algebra.Geometric Algebra is a powerful new form of mathematics that vastly simplifiescomplex geometric calculations. Geometric Algebra has its origins in the ratheresoteric academic discipline of theoretical cosmology, but it has now beendeveloped for application in a wide variety of disparate commercial applicationssuch as computer graphics in computer games and electromagnetic modelling whichis used, amongst other things, for optimising the design of mobile phoneantennas and reducing the radar signature of ships and planes. One of the main differentiators between computer games is the speed and qualityof rendering of the graphics. With best-selling games generating severalhundred million dollars for their developers, the quest for better and fastergraphics engines is relentless. Geomerics' technology provides a step-changeimprovement over the competition, and is set to revolutionise the market.Overall the market for computer games is currently worth more than $30bn andgrowing rapidly, and the market for graphics within these games is worth over$600m per year. Current electromagnetic modelling techniques do not give the accuracy requiredin many applications, because the processing power required is prohibitive.Geomerics' technology has already been used to resolve complex electromagneticmodelling problems that rival systems have been unable to solve. Theelectromagnetic modelling market is worth in excess of $100m per year and thereis also considerable latent demand. This new approach in applying geometric algebra has been developed by a group offour leading academics from the University of Cambridge: Professor AnthonyLasenby (Professor of Astrophysics and Cosmology), Dr Mike Hobson (UniversityReader in Astrophysics), Dr Chris Doran (EPSRC Advanced Research Fellow) and DrJoan Lasenby (Lecturer in Engineering). Geomerics has also engaged ProfessorDavid Hestenes of Arizona State University (the original inventor of geometricalgebra) and Professor Alyn Rockwood of Colorado School of Mines (a geometricalgebra and computer graphics expert) in an advisory capacity. In accordance with ANGLE's Progeny(R) process for creating new ventures, ANGLE'splan is to build a strong commercial offering in each of the key marketssequentially, seeking a return on its investment in the medium term.Simultaneously, development work will continue on the geometric algebraplatform. ANGLE expects to spend up to £500,000 in the Progeny(R) venture, whichis presently wholly owned by ANGLE. Commenting on the collaboration with ANGLE, Professor Lasenby said: 'We have been developing the mathematics and technology behind Geomerics for anumber of years, and now is the perfect time to apply it to commercialapplications. We are delighted that ANGLE will be commercialising ourtechnology.' ANGLE's Chief Executive Andrew Newland said: 'Computer graphics and electromagnetic modelling are large, growing markets.Geomerics' technology is truly leading-edge and we believe it will revolutionisea wide range of fields. We are delighted to be working with such a high calibreof academic inventors.' For further information: ANGLE plcAndrew Newland, Chief Executive 01483 295830Stephen Bence, Associate Director - Ventures UK 01223 472745 Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.